Acasti announces third fiscal quarter 2024 financial results and business highlights

Princeton, n.j., feb. 12, 2024 (globe newswire) -- acasti pharma inc. (nasdaq: acst) (acasti or the company), a late-stage, biopharma company advancing gtx-104, its novel formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced financial results and business highlights for the quarter ended december 31, 2023.
ACST Ratings Summary
ACST Quant Ranking